IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Sandoz Gains Biosimilar Approval

7:45 AM MDT | July 13, 2009

Sandoz (Holzkirchen, Germany), a division of Novartis, says it has received marketing authorization for the first ever biosimilar to be sold in Japan. Approval of the product, recombinant human growth hormone somatropin, paves the way for greater market access for high-quality biopharmaceuticals in Japan, Sandoz says. Japan is the second-largest pharmaceuticals market after the U.S. Biosimilars are approved versions of innovator biopharmaceutical products, following patent expiry. The Sandoz product is approved for the treatment of growth hormone deficiency in...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa